Amgen's Matsuda offers grist for the regulatory rumor mill

Share this article:
Marketers may soon need to reconsider their online strategies in light of new regulatory developments, Mas Matsuda, associate general counsel and executive director at Amgen, told attendees at an e-marketing conference today.

Matsuda posed a series of hypothetical questions to just over 100 attendees of CBI's 8th annual Forum on e-Marketing, including: “What if a two-year moratorium is put on e-marketing? What if Medicare reimbursements are reduced for DTC advertisers? What if DTC advertisers are required to fund a public health education initiative?”

Matsuda also pointed to academic detailing legislation introduced in Congress last July that could restrict access to physicians. The Independent Drug Education and Outreach Act would fund independent detailing geared toward protecting physicians from me-too drugs that drive up healthcare expenses, said Matsuda.

“The goal is to generate healthcare savings while ensuring that Americans receive improved, more effective care,” Matsuda said of the bill.  

Regarding PhRMA's updated code on gifts for doctors, Matsuda noted that a stethoscope would not be an appropriate gift, since it is designed for patient treatment and not physician education.  

To navigate the ever-changing regulatory environment, Matsuda recommended that marketers “engage your respective legal and regulatory teams early and often.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...